Bioray Biotech Co., Ltd (TPEX:7561)

Bioray Biotech Statistics

Total Valuation

Bioray Biotech has a market cap or net worth of TWD 690.82 million. The enterprise value is 587.26 million.

Market Cap	690.82M
Enterprise Value	587.26M

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Bioray Biotech has 29.59 million shares outstanding. The number of shares has decreased by -2.01% in one year.

Current Share Class	29.59M
Shares Outstanding	29.59M
Shares Change (YoY)	-2.01%
Shares Change (QoQ)	-1.55%
Owned by Insiders (%)	11.18%
Owned by Institutions (%)	n/a
Float	13.95M

Valuation Ratios

The trailing PE ratio is 22.69.

PE Ratio	22.69
Forward PE	n/a
PS Ratio	3.00
PB Ratio	1.57
P/TBV Ratio	1.57
P/FCF Ratio	22.10
P/OCF Ratio	20.60
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.96, with an EV/FCF ratio of 18.79.

EV / Earnings	19.25
EV / Sales	2.55
EV / EBITDA	9.96
EV / EBIT	16.54
EV / FCF	18.79

Financial Position

The company has a current ratio of 7.15, with a Debt / Equity ratio of 0.12.

Current Ratio	7.15
Quick Ratio	5.29
Debt / Equity	0.12
Debt / EBITDA	0.87
Debt / FCF	1.64
Interest Coverage	45.13

Financial Efficiency

Return on equity (ROE) is 7.12% and return on invested capital (ROIC) is 4.44%.

Return on Equity (ROE)	7.12%
Return on Assets (ROA)	4.13%
Return on Invested Capital (ROIC)	4.44%
Return on Capital Employed (ROCE)	7.36%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.43
Inventory Turnover	2.17

Taxes

In the past 12 months, Bioray Biotech has paid 7.73 million in taxes.

Income Tax	7.73M
Effective Tax Rate	20.22%

Stock Price Statistics

The stock price has increased by +3.78% in the last 52 weeks. The beta is 0.18, so Bioray Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.18
52-Week Price Change	+3.78%
50-Day Moving Average	25.07
200-Day Moving Average	23.28
Relative Strength Index (RSI)	38.14
Average Volume (20 Days)	2,215

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bioray Biotech had revenue of TWD 230.06 million and earned 30.50 million in profits. Earnings per share was 1.03.

Revenue	230.06M
Gross Profit	107.59M
Operating Income	35.52M
Pretax Income	38.23M
Net Income	30.50M
EBITDA	50.86M
EBIT	35.52M
Earnings Per Share (EPS)	1.03

Balance Sheet

The company has 154.87 million in cash and 51.32 million in debt, giving a net cash position of 103.56 million or 3.50 per share.

Cash & Cash Equivalents	154.87M
Total Debt	51.32M
Net Cash	103.56M
Net Cash Per Share	3.50
Equity (Book Value)	439.96M
Book Value Per Share	14.87
Working Capital	253.05M

Cash Flow

In the last 12 months, operating cash flow was 33.54 million and capital expenditures -2.28 million, giving a free cash flow of 31.26 million.

Operating Cash Flow	33.54M
Capital Expenditures	-2.28M
Free Cash Flow	31.26M
FCF Per Share	1.06

Margins

Gross margin is 46.77%, with operating and profit margins of 15.44% and 13.26%.

Gross Margin	46.77%
Operating Margin	15.44%
Pretax Margin	16.62%
Profit Margin	13.26%
EBITDA Margin	22.11%
EBIT Margin	15.44%
FCF Margin	13.59%

Dividends & Yields

Bioray Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.01%
Shareholder Yield	2.01%
Earnings Yield	4.42%
FCF Yield	4.52%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	7